This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ASM journals
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Hermsen, E. D.
Right arrow Articles by Rotschafer, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Hermsen, E. D.
Right arrow Articles by Rotschafer, J. C.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2005, p. 1633-1635, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1633-1635.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.

Mutant Prevention Concentrations of ABT-492, Levofloxacin, Moxifloxacin, and Gatifloxacin against Three Common Respiratory Pathogens

Elizabeth D. Hermsen,1 Laurie B. Hovde,1 George N. Konstantinides,2 and John C. Rotschafer1*

College of Pharmacy, University of Minnesota, Minneapolis,1 Saint John's University, Collegeville, Minnesota2

Received 20 May 2004/ Returned for modification 15 September 2004/ Accepted 23 November 2004

The purpose of this study was to compare the mutant prevention concentration (MPC) of ABT-492 to those of levofloxacin, moxifloxacin, and gatifloxacin against Streptococcus pneumoniae, Haemophilus influenzae, and Moraxella catarrhalis. The fluoroquinolones had comparable mutation selection windows, which is the ratio of MPC/MIC, for all isolates.

* Corresponding author. Mailing address: College of Pharmacy, University of Minnesota, 9-157 WDH, 308 Harvard St. SE, Minneapolis, MN 55455. Phone: (612) 624-2183. Fax: (612) 625-1140. E-mail: rotsc001{at}umn.edu.

Antimicrobial Agents and Chemotherapy, April 2005, p. 1633-1635, Vol. 49, No. 4
0066-4804/05/$08.00+0     doi:10.1128/AAC.49.4.1633-1635.2005
Copyright © 2005, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Credito, K., Kosowska-Shick, K., McGhee, P., Pankuch, G. A., Appelbaum, P. C. (2010). Comparative Study of the Mutant Prevention Concentrations of Moxifloxacin, Levofloxacin, and Gemifloxacin against Pneumococci. Antimicrob. Agents Chemother. 54: 673-677 [Abstract] [Full Text]  


Copyright © 2010 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»